A Phase 1/2 interventional study of CM326 and Placebo in Moderate-to-severe Atopic Dermatitis, sponsored by Keymed Biosciences Co.Ltd. Status unknown at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-03-09.
Sponsored by Keymed Biosciences Co.Ltd · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Dermatitis, Atopic by Keymed Biosciences Co.Ltd — 4 open to participants now, 5 under way, 3 of them phase 3. Dermatitis, Atopic · Keymed Biosciences Co.Ltd.
Among the 18 studies in Dermatitis, Atopic by Keymed Biosciences Co.Ltd, this one is the 15th largest by planned enrollment, is one of 4 that started in 2022, is one of 3 in phase 1/2, and was the 4th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →4 of the 18 studies in Dermatitis, Atopic by Keymed Biosciences Co.Ltd are open now, in 1 country. Recruiting first, the newest first:
Keymed Biosciences Co.Ltd · Sites in China
Ages 18+
Keymed Biosciences Co.Ltd · Sites in China
Ages 18–75
Keymed Biosciences Co.Ltd · Sites in China
Ages 2–12
Keymed Biosciences Co.Ltd · Sites in China
Ages 2–11
By country, each count listing its studies:
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 12 · Phase 3 5
First in 2020; this study’s year is marked. 4 started in 2022.
This study's planned enrollment of 54 is below the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 170 across the 18 interventional studies. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Keymed Biosciences Co.Ltd is the lead sponsor of 68 studies on the registry; 34 are open to participants now.
1 of the studies in Dermatitis, Atopic by Keymed Biosciences Co.Ltd that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07106372Phase 3Keymed Biosciences Co.LtdA Study of Stapokibatrt in Children Subjects With Atopic Dermatitis | 2027-02 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies in Dermatitis, Atopic by Keymed Biosciences Co.Ltd, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multi-center, randomized, double blind, placebo-controlled multiple dose escalation study to evaluate the safety, tolerance, PK, PD, immunogenicity and preliminary efficacy of CM326 in moderate-severe AD subjects.
The study consists of 3 periods, a up-to-4-week Screening Period, a 12-week randomized Treatment Period and a 12-week Safety Follow-up Period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
55mg for 6 doses, every 2 weeks, subcutaneous (SC)
Biological: CM326
110mg for 6 doses, every 2 weeks, subcutaneous (SC)
Biological: CM326
110mg for 3 doses, every 4 weeks, subcutaneous (SC)
Biological: CM326
220mg for 6 doses, every 2 weeks, subcutaneous (SC)
Biological: CM326
220mg for 3 doses, every 4 weeks, subcutaneous (SC)
Biological: CM326
Placebo for 6 doses, every 2 weeks, subcutaneous (SC) and placebo for 3 doses, every 4 weeks, subcutaneous (SC)
Other: Placebo
CM326 injection
Placebo
Incidence of Adverse Events (AE)
Incidence of AEs, including any abnormal physical examinations, abnormal vital signs, abnormal ECG, and abnormal lab testing.
Time frame: Up to week 24
Pharmacokinetics (PK) parameter: Time to reach peak concentration (Tmax)
Time to reach peak concentration (Tmax)
Time frame: Up to Week 24
Pharmacokinetics (PK) parameter : Peak Plasma concentration (Cmax)
Peak Plasma concentration (Cmax)
Time frame: Up to Week 24
Pharmacokinetics (PK) parameter : Area under the plasma concentration-time curve (AUC)
Area under the plasma concentration-time curve (AUC)
Time frame: Up to Week 24
Pharmacokinetics (PK) parameter : Clearance rate (CL/F)
Clearance rate (CL/F)
Time frame: Up to Week 24
Pharmacokinetics (PK) parameter : Elimination half life (T1/2z)
Elimination half life (T1/2z)
Time frame: Up to Week 24
Pharmacodynamics (PD): Changes from baseline in serum thymus activation regulation chemokine (TARC) concentration after CM326 administration
Changes from baseline in serum thymus activation regulation chemokine (TARC) concentration after CM326 administration
Time frame: Up to Week 24
Pharmacodynamics (PD): Changes from baseline in eosinophil count after CM326 administration
Changes from baseline in eosinophil count after CM326 administration
Time frame: Up to Week 24
Pharmacodynamics (PD): Changes from baseline in serum total immunoglobulin E (IgE) concentration after CM326 administration
Changes from baseline in serum total immunoglobulin E (IgE) concentration after CM326 administration
Time frame: Up to Week 24
Pharmacodynamics (PD): Changes from baseline in plasma interleukin-5 (IL-5) concentration after CM326 administration
Changes from baseline in plasma interleukin-5 (IL-5) concentration after CM326 administration
Time frame: Up to Week 24
Pharmacodynamics (PD): Changes from baseline in plasma interleukin-13 (IL-13) concentration after CM326 administration
Changes from baseline in plasma interleukin-13 (IL-13) concentration after CM326 administration
Time frame: Up to Week 24
Pharmacodynamics (PD): Changes from baseline in serum periostin concentration after CM326 administration
Changes from baseline in serum periostin concentration after CM326 administration
Time frame: Up to Week 24
Immunogenicity: anti-drug antibody (ADA) and neutralizing antibody (Nab)
Detection of anti-drug antibody (ADA) and neutralizing antibody (Nab)
Time frame: Up to Week 24
Proportion of patients with Investigator's Global Assessment (IGA) score = 0-1 at each visit
IGA is a 6-point scale ranging from 0 (clear) to 5 (very severe)
Time frame: Up to Week 24
Proportion of patients with IGA reduction from baseline of ≥2 points at each visit
IGA is a 6-point scale ranging from 0 (clear) to 5 (very severe)
Time frame: Up to Week 24
Proportion of patients with Eczema Area and Severity Index (EASI)-50 (≥50 percent reduction in EASI scores from baseline) at each visit
The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 to 72 points, with the higher scores reflecting the worse severity of AD
Time frame: Up to Week 24
Proportion of patients with Eczema Area and Severity Index (EASI)-75 (≥75 percent reduction in EASI scores from baseline) at each visit
The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 to 72 points, with the higher scores reflecting the worse severity of AD
Time frame: Up to Week 24
Proportion of patients with Eczema Area and Severity Index (EASI)-90 (≥90 percent reduction in EASI scores from baseline) at each visit
The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 to 72 points, with the higher scores reflecting the worse severity of AD
Time frame: Up to Week 24
Change from baseline in Eczema Area and Severity Index (EASI) score at each visit
The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 to 72 points, with the higher scores reflecting the worse severity of AD
Time frame: Up to Week 24
Proportion of patients with reduction of Pruritus Numerical Rating Scale (NRS) of ≥3 and ≥4 points from baseline
The range of NRS is from 0 (no itch)-10 (worst imaginable itch)
Time frame: Up to Week 24
Percent change from baseline in Numerical Rating Scale (NRS)
The range of NRS is from 0 (no itch)-10 (worst imaginable itch)
Time frame: Up to Week 24
Body surface area (BSA) of involvement of atopic dermatitis
Change from baseline in percent of BSA
Time frame: Up to Week 24
Changes from baseline in Dermatology Life Quality Index (DLQI) at each visit
The DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of AD disease symptoms and treatment on quality of life
Time frame: Up to Week 24
Started Feb 2022 (actual). Primary completion is estimated for Jan 2023, 11 months after the start.
Of 25 industry-sponsored phase 1/2 interventional studies under Dermatitis, Atopic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 38. This study's planned 11 months is below that.
Counting every sponsor, half of 29 studies reached it within 22 months; a quarter within 8 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ocankitug